Investor Presentation

August 11, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Ref.: Disclosure under regulation 30 read with regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir, Pursuant to the provisions of regulation 30 read with regulation 46 of the Listing Regulations, please find attached the Investor Presentation on the unaudited financial results for the quarter ended on June 30, 2026. Please find the same in order. Thanking you, Yours faithfully, For, ZYDUS LIFESCIENCES LIMITED DHAVAL N. SONI COMPANY SECRETARY AND COMPLIANCE OFFICER MEMBERSHIP NO. FCS7063 Encl.: As above Zydus Lifesciences Limited Earnings Presentation: Q1 FY27 11th August 2026 Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the Company’s activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “projects”, “expects”, “intends”, “may”, “will”, “seeks” or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company’s intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates. • By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward- looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company’s actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc. • The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. This document is just a Presentation and is not intended to be a “prospectus” or “offer document” or a “private placement offer letter” (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company’s equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company’s securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever. Q1 FY27: At a Glance Revenues from Highlights of Q1 FY27 Operations ❑ Total revenues grew 22% YoY. Rs. 80,170 mn Rs. 6,424 mn ❑ Within Pharmaceutical business, 22% YoY 8% of revenues ➢ India branded formulations sustained strong growth momentum and outpaced the market growth for yet another quarter. EBITDA & Margin % Net Profit ➢ North America formulations business grew sequentially driven by sustained volume expansion and new launches. Rs. 19,294 mn ➢ International Markets business sustained its growth trajectory Rs. 9,398 mn driven by strong demand. 24.1% of revenues 35.9% YoY 7.6% YoY ❑ Consumer Wellness business continued to hold dominant market share in key brands in India; International business including CCL business delivered robust performance on a like-to-like basis. Business-wise Sales Break-up (Rs. mn) and YoY Growth ❑ MedTech business continued to enhance capabilities in focused therapies. Medtech India Form ❑ EBITDA margin stood at 24.1%, down 770 bps YoY. 4% 23% Consumer ▲20% ❑ Capex (organic) for the quarter: Rs. 5,852 mn. Wellness ❑ Net Debt: Rs. 59,041 mn (as at 30-Jun’26) ▲67% Pharma Business 78% Regulatory Updates Total ▲9% Alliances 0.2% 78,020 ▲21% ❑ Injectable manufacturing facility at Zydus Biotech Park received an 2% Establishment Inspection Report (EIR) with a Voluntary Action Indicated North America ▲15% (VAI) classification following a GMP surveillance inspection conducted in IM ▼3% April - May 2026. ▲34% Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 80,170 72.8% 72.4% 73.2% 74.0 % 72.1% 75,870 65,737 68,645 56,107 57,772 61,232 47,842 50,282 44,327 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Total R&D (Rs. mn) and % to Revenues EBITDA (Rs. mn) and EBITDA Margin % 7.4 % 7.9% 8.8% 9.2% 8.0 % 31.8 % 32.9% 26.5 % 33.7 % 24.1% 25,544 6,982 6,424 6,074 20,885 20,158 19,294 18,164 4,856 4,820 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 4 Key Financial Metrics (2/2) Reported PAT (Rs. mn) Organic Capex (Rs. mn) 5,852 14,668 12,586 12,725 4,911 4,637 10,421 4,020 9,398 3,577 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 [Showing first 8,000 characters — download PDF for full document]